©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 21, 2013; 19(19): 2864-2882
Published online May 21, 2013. doi: 10.3748/wjg.v19.i19.2864
Published online May 21, 2013. doi: 10.3748/wjg.v19.i19.2864
Table 1 Essential steps of herbal hepatotoxicity assessments
| Quality specifications |
| Herbal product quality |
| Good agricultural practices |
| Good manufacturing practices |
| Definition of plant family, subfamily, species, subspecies, and variety |
| Definition of plant part |
| Definition of solvents and solubilizers |
| Lack of impurities, adulterants, and misidentifications |
| Minimum of batch and product variability |
| Lack of variety to variety variability |
| Clinical assessment quality |
| Brand name with details of ingredients, plant parts, batch number, and expiration date |
| Identification as herbal drug or herbal supplement |
| Herb as an ingredient of a polyherbal product or an undetermined herbal product |
| Manufacturer with address |
| Indication of herbal use with dates of symptoms leading to herbal treatment |
| Daily dose with details of the application form |
| Exact date of herb start and herb end |
| Accurate dates of emerging new symptoms after herb start in chronological order |
| Accurate date of initially increased liver values |
| Timeframes of challenge, latency period, and dechallenge |
| Verification or exclusion of a temporal association |
| Provided temporal association is verified, evaluation of a causal relationship |
| Gender, age, body weight, height, body mass index |
| Ethnicity, profession |
| Past medical history regarding general diseases and specifically liver diseases |
| ALT value initially including normal range |
| ALT values during dechallenge at least on days 8 and 30, as well as later on |
| ALT values during dechallenge to exclude a second peak |
| ALT normalization with exact date and actual value |
| ALP value initially including normal range |
| ALP values during dechallenge up to 180 d, as well as later on |
| ALP values during dechallenge to exclude a second peak |
| ALP normalization with exact date and actual value |
| AST value initially including normal range |
| Laboratory criteria for definition of hepatotoxicity and its pattern |
| Definition of risk factors such as age and alcohol |
| Alcohol and drug use |
| Statement regarding actual treatment including steroids or ursodesoxycholic acid |
| Assessment of preexisting and coexisting liver unrelated diseases |
| Assessment of preexisting and coexisting liver diseases |
| Consideration of the several hundreds of other possible liver diseases |
| Providing details to exclude alternative diagnoses |
| Assessment and exclusion of hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis E virus, cytomegalovirus, Epstein-Barr virus, HSV, VZV |
| Liver and biliary tract imaging including color Doppler sonography of liver vessels |
| Specific evaluation of alcoholic, cardiac, autoimmune, and genetic liver diseases |
| Individual quantitative score of each alternative diagnosis |
| Comedicated synthetic drugs, herbal drugs, herbal and other dietary supplements |
| Definition of and search for accidental, unintended reexposure |
| Assessing of unintended reexposure |
| Search for evidence of prior known hepatotoxicity of the suspected herb |
| Assessing of known hepatotoxicity caused by the herb |
| Qualified data acquisition and documentation of complete data |
| Transparent presentation of all data |
| Causality assessment quality |
| Prospective assessment by the physician suspecting herb induced liver injury |
| Structured and quantitative method |
| Liver specific causality assessment method validated for hepatotoxicity |
| Use of the CIOMS scale |
| Gathering of all data required for the CIOMS scale item by item |
| Presentation of individual CIOMS items and of scores to regulatory agency |
| Gathering all clinical data and presentation to regulatory agency |
| Excluding all alternative causes and presentation to regulatory agency |
| Regulatory case assessment by skilled hepatologist with clinical experience |
| Regulatory assessment with assistance of external experts |
| Transparent presentation of regulatory verified causality assessment results |
- Citation: Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J Gastroenterol 2013; 19(19): 2864-2882
- URL: https://www.wjgnet.com/1007-9327/full/v19/i19/2864.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i19.2864